Market Research Logo

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020

Various factors have contributed to the rise in demand for biopharmaceutical products such as biologics and biosimilars. Some of these factors include the rising pressure to reduce healthcare expenditure, growing demand for cost-effective alternatives, growing burden of chronic diseases, and growing aging population. Biosimilars are similar versions of their corresponding patented biologic drugs, and are similar with regards to their quality, safety, and efficacy. The global biosimilars market is estimated to be worth $2.29 billion in 2015, and is poised to grow at a CAGR of 22.1% during the forecast period.

This report studies and analyzes the biosimilars market by product and application. On the basis of products, the biosimilars market is segmented into recombinant nonglycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant nonglycosylated proteins market is further segmented into insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormones; whereas, the recombinant glycosylated proteins market is further segmented into erythropoietin, monoclonal antibodies, and follitropin. The recombinant peptides market is segmented into calcitonin and glucagon. The recombinant glycosylated proteins segment is expected to witness the highest growth rate owing to the increased demand for monoclonal antibodies in the treatment of cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. On the other hand, the recombinant nonglycosylated proteins segment accounts for the largest share of the market in 2015. The insulin segment is poised to be the fastest-growing segment of the recombinant nonglycosylated proteins market, growing at a CAGR of 28.1% from 2015 to 2020. Growth in this insulin market is attributed to the rising incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of insulin.

On the basis of applications, the biosimilars market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and other applications (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure).

Geographically, Europe is expected to account for the largest share of the global biosimilars market in 2015 followed by Asia-Pacific. The large share of the European region can be attributed to the rising budgetary pressures to reduce healthcare expenditure, increasing aging population, growing demand for cost-effective alternatives, rising incidences of various diseases, and government initiatives. On the other hand, stringent regulatory environment, high manufacturing complexities and costs, and high-entry barriers are considered to hinder its market growth.

The global biosimilars market is highly competitive, with a large number of big and small market players. As of 2014, the global biosimilars market was dominated by Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel). Furthermore, new product launches and expansions are the major strategies adopted by major players to achieve growth in this market.

Reasons to Buy the Report:
From an insight perspective, this research report focused on various levels of analysis—industry analysis (industry trends and Porter’s five forces model), market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments in the biosimilars market; and high-growth regions/countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
Market Penetration: Comprehensive information on biosimilar products offered by the top 10 players in the biosimilars market. The report analyzes the biosimilars market by product and application across geographies

Product Development/Innovation: Detailed insights on research and development activities and new product launches in the biosimilars market

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various biosimilar products across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the biosimilars market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
      • MARKET SEGMENTATION
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATIONS
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • MARKET SIZE ESTIMATION
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • MARKET SHARE ESTIMATION
      • KEY DATA FROM SECONDARY SOURCES
      • KEY DATA FROM PRIMARY SOURCES
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
    • INTRODUCTION
  • PREMIUM INSIGHTS
    • OVERALL BIOSIMILARS MARKET
    • BIOSIMILARS MARKET, BY TYPE & REGION
    • BIOSIMILARS MARKET, BY COUNTRIES
    • RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET, BY TYPE
    • LIFECYCLE ANALYSIS, BY REGION
  • MARKET OVERVIEW
    • INTRODUCTION
    • BIOSIMILARS MARKET SEGMENTATION
      • BY PRODUCT
      • BY APPLICATION
      • BY REGION
    • MARKET DYNAMICS
      • DRIVERS
        • Table BIOSIMILARS MARKET: MAJOR COLLABORATIONS (2012-2015)
        • Table BIOLOGICS GOING OFF-PATENT TO BOOST THE MARKET GROWTH FOR BIOSIMILARS
      • RESTRAINTS
        • Table HIGH MANUFACTURING COMPLEXITIES AND COSTS RESTRAINING THE GROWTH FOR THE BIOSIMILARS MARKET
      • OPPORTUNITIES
        • Table LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
        • Table GROWTH PROSPECTS IN EMERGING MARKETS FUEL THE MARKET GROWTH
      • CHALLENGES
        • Table STRINGENT REGULATORY REQUIREMENTS IN MAJOR COUNTRIES IS A MAJOR CHALLENGE FOR THE BIOSIMILARS MARKET
      • BURNING ISSUES
  • INDUSTRY INSIGHTS
    • INTRODUCTION
    • PORTER'S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • INTENSITY OF RIVALRY
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
    • KEY PIPELINE PRODUCTS
      • Table BIOSIMILARS IN CLINICAL TRIALS
    • REGULATORY OUTLOOK
      • NORTH AMERICA
        • Table STATUS OF REGULATORY PATHWAY IN NORTH AMERICA REGION
      • EUROPE
        • Table SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
      • ASIA-PACIFIC
        • Table STATUS OF REGULATORY PATHWAY IN THE ASIA-PACIFIC REGION
      • REST OF THE WORLD
        • Table STATUS OF REGULATORY PATHWAY IN THE ROW
    • BIOSIMILARS SERVICES INDUSTRY INSIGHTS
      • INTRODUCTION
      • CONTRACT MANUFACTURING ORGANIZATIONS
        • Table JOINT VENTURES BETWEEN CMOS & PHARMACEUTICAL COMPANIES FOR BIOSIMILARS
      • CONTRACT RESEARCH ORGANIZATIONS
      • OTHER SERVICES (NONCLINICAL & BIOINFORMATICS)
  • BIOSIMILARS MARKET, BY TYPE OF PRODUCT
    • INTRODUCTION
      • Table BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION)
    • RECOMBINANT NON-GLYCOSYLATED PROTEINS
      • Table RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • Table EUROPE: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • INSULIN
        • Table INSULIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
        • Table RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM)
        • Table LIST OF APPROVED PRODUCTS FROM 2012 TO 2015.
        • Table GRANULOCYTE COLONY-STIMULATING FACTOR MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • INTERFERONS
        • Table INTERFERONS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
    • RECOMBINANT GLYCOSYLATED PROTEINS
      • Table RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • Table EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • ERYTHROPOIETIN (EPO)
        • Table ERYTHROPOIETIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • MONOCLONAL ANTIBODIES (MABS)
        • Table MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • FOLLITROPIN
        • Table FOLLITROPIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
    • RECOMBINANT PEPTIDES
      • Table RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table RECOMBINANT PEPTIDES MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • Table EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
      • GLUCAGON
        • Table GLUCAGON MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • CALCITONIN
        • Table CALCITONIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • BIOSIMILARS MARKET, BY APPLICATION
    • INTRODUCTION
      • Table BIOSIMILARS MARKET SIZE, BY APPLICATION, 2012-2019 ($MILLION)
    • ONCOLOGY
      • Table BIOSIMILARS MARKET SIZE FOR ONCOLOGY, BY REGION, 2012-2019 ($MILLION)
    • BLOOD DISORDERS
      • Table BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2012-2019 ($MILLION)
    • CHRONIC AND AUTOIMMUNE DISEASES
      • Table BIOSIMILARS MARKET SIZE FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION, 2012-2019 ($MILLION)
    • GROWTH HORMONE DEFICIENCY
      • Table BIOSIMILARS MARKET SIZE FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2012-2019 ($MILLION)
    • INFECTIOUS DISEASES
      • Table BIOSIMILARS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2012-2019 ($MILLION)
    • OTHER APPLICATIONS
      • Table BIOSIMILARS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2012-2019 ($MILLION)
  • BIOSIMILARS MARKET, BY REGION
    • INTRODUCTION
      • Table BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
      • U.S.
        • Table U.S.: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • CANADA
        • Table CANADA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
    • EUROPE
      • Table EUROPE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
      • Table EUROPE: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table EUROPE: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
      • U.K.
        • Table U.K.: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • GERMANY
        • Table GERMANY: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • FRANCE
        • Table FRANCE: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • SPAIN
        • Table SPAIN: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • ITALY
        • Table ITALY: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • REST OF EUROPE
        • Table ROE: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
    • ASIA-PACIFIC
      • Table ASIA-PACIFIC: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table ASIA-PACIFIC: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
      • CHINA
        • Table CHINA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • INDIA
        • Table INDIA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • JAPAN
        • Table JAPAN: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • SOUTH KOREA
        • Table SOUTH KOREA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • REST OF ASIA-PACIFIC (ROAPAC)
        • Table ROAPAC: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
    • REST OF THE WORLD (ROW)
      • Table ROW: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
      • Table ROW: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table ROW: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table ROW: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
      • Table ROW: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • MARKET SHARE ANALYSIS
    • COMPETITIVE SITUATION AND TRENDS
      • NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS
        • Table RECENT NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS, 2012-2015
      • AGREEMENTS AND COLLABORATIONS
        • Table RECENT AGREEMENTS AND COLLABORATIONS, 2012-2015
      • EXPANSIONS
        • Table RECENT EXPANSIONS, 2012-2015
      • ACQUISITIONS
        • Table RECENT ACQUISITIONS 2012-2015
      • OTHER DEVELOPMENTS
        • Table RECENT OTHER DEVELOPMENTS, 2012-2015
  • COMPANY PROFILES
    • INTRODUCTION
    • HOSPIRA, INC.
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG)
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMANN-LA ROCHE LTD.)
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
    • AMGEN
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
    • BIOCON LTD.
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
    • DR. REDDY'S LABORATORIES
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
    • CELLTRION INC.
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
    • MYLAN INC.
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
    • MERCK KGAA
      • BUSINESS OVERVIEW
      • PRODUCT OFFERINGS
      • RECENT DEVELOPMENTS
  • APPENDIX
    • INSIGHTS FROM INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report